XR Health acquires Swing Therapeutics
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Swing Therapeutics was acquired by medical virtual reality company XR Health; Swing develops an FDA-cleared digital treatment for fibromyalgia.
- XR Health CEO Eran Orr said the deal terms were not disclosed because "it won't be the last" acquisition, framing this as the start of a broader roll-up strategy.
- Swing is XR Health's sixth acquisition in the past two years, and the deal signals a strategic shift toward positioning the platform as a go-to destination for disease-specific digital treatments.
- XR Health currently hosts dozens of apps and logged one million user sessions in 2025, with VR offerings spanning meditation, cognitive behavioral therapy, mental health, pain, and hot flashes.
- XR Health's existing VR treatment packages are registered with the FDA but not cleared — making Swing's FDA-cleared fibromyalgia product a regulatory step-up for the combined platform.
Why it matters: This is XR Health's sixth acquisition in two years, signaling an explicit roll-up strategy (in CEO Eran Orr's words, "it won't be the last") to consolidate disease-specific digital therapeutics onto one VR platform. The Swing deal specifically gives XR Health what it currently lacks: an FDA-cleared product, rather than FDA-registered ones — a regulatory distinction that matters for clinicians prescribing digital treatments.
